Published: Tue, February 06, 2018
Finance | By Loren Pratt

You Need To Know About Analysts Ratings on - Abbott Laboratories (ABT)


Institutions own 71.75% of Abbott Laboratories (ABT)'s shares. Typically, if the value heads above -20, the stock may be considered to be overbought. Abbott Labs now has $107.38B valuation.

Recent insider trends for Abbott Laboratories (NYSE:ABT) have caught the attention of investors. The shares were sold at an average price of $55.00, for a total value of $3,913,635.00. Abbott Laboratories (NYSE:ABT) has risen 15.90% since February 5, 2017 and is uptrending. The company's 3-months average volume stands at 6.38 million. The firm offers Veeva Commercial Cloud, a suite of multichannel customer relationship management applications, which allow pharmaceutical and biotechnology companies to target and support sales and marketing to physicians, other healthcare professionals, and healthcare organizations through various touch points, including in-person, email, and online; and Veeva Vault, a cloud enterprise content management platform and suite of applications for managing commercial functions, including medical, sales, and marketing, as well as research and development functions, such as clinical, regulatory, and quality. It has a 13.33 P/E ratio. It also provides Veeva Network master data management solutions for the management of customer master and product master data. (NYSE:WSM) to report earnings on March, 21. The business's revenue for the quarter was up 42.3% on a year-over-year basis. sell-side analysts expect that Abbott Laboratories will post 2.86 earnings per share for the current year. They are also projecting the Low EPS estimate of $0.56 and the High EPS estimate of $0.59. The healthcare product maker reported $0.74 EPS for the quarter, topping the consensus estimate of $0.73 by $0.01. The firm offers savings and protection products in the lower income and foundation market; lending products; wealth creation and protection, and asset management products to middle income and high-net worth customers; retirement and group risk products to institutional and corporate investors and employers; access to various investment offerings, styles, and asset classes; life, property, and casualty insurance products; mandatory and voluntary pensions, offshore investment products, and institutional asset management solutions; and services to a network of independent financial advisers, wealth managers, and other institutions. Kayne Anderson Rudnick Investment Management Llc owns 2.29 million shares or 2.58% of their U.S. portfolio. Following the completion of the transaction, the insider now owns 144,955 shares in the company, valued at approximately $7,972,525. Linscomb Williams invested in 48,703 shares. The average volume was noted at 6382.74K shares while its relative volume was seen at 1.8. Overall, 3.86 Million shares exchanged hands versus its average volume of $1.59 Million.

Traders will often use multiple moving averages to analyze a single security. Veeva Systems Inc. (VEEV) has risen 114.93% since February 5, 2017 and is uptrending.

Ratings analysis reveals 75% of Veeva Systems's analysts are positive. The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 1.90, which implies that analysts are generally bullish in their outlook for ABT over the next year. Healthsouth had 32 analyst reports since July 31, 2015 according to SRatingsIntel. Gabelli maintained the stock with "Buy" rating in Friday, July 21 report. Its down 0.01, from 0.88 in 2017Q2. It turned negative, as 47 investors sold ABT shares while 563 reduced holdings. Dimensional Fund Advisors LP raised its position in Abbott Laboratories by 28.6% in the second quarter. Clear Harbor Asset Mgmt Ltd Liability Corporation reported 0.18% stake. Moreover, Tci Wealth Advisors has 0.54% invested in Abbott Laboratories (NYSE:ABT). Texas-based American Bankshares has invested 0.14% in Abbott Laboratories (NYSE:ABT). Hugh Johnson Advsrs Lc holds 1.08% or 67,598 shares in its portfolio. Sterling Mgmt Limited Liability Corp, a North Carolina-based fund reported 4,325 shares. BANK OF NEW YORK MELLON CORP also announced decreased position in Abbott Laboratories (ABT) during the quarter. Bancorporation Of Stockton owns 11,194 shares for 0.66% of their portfolio. Canal Insur owns 0.75% invested in Abbott Laboratories (NYSE:ABT) for 40,000 shares. 1,900 are owned by Next Fincl Group Inc. First Republic Invest Management Incorporated stated it has 4,741 shares or 0% of all its holdings. Shareholders of record on Friday, January 12th will be issued a dividend of $0.28 per share. The Relative Volume value measured for Abbott Laboratories stands at 1.75. Huntington Natl Bank reported 1 shares.


Since August 16, 2017, it had 0 insider buys, and 8 sales for $41.44 million activity.

In related news, insider Daniel Gesua Sive Salvadori sold 71,157 shares of the firm's stock in a transaction dated Tuesday, November 14th. Another trade for 52,700 shares valued at $2.74M was made by Contreras Jaime on Friday, September 22.

Currently, the 14-day ADX for Abbott Laboratories (ABT) is sitting at 42.02. 27,733 shares were sold by Blaser Brian J, worth $1.73M. Lingohr And Partner Asset Gmbh holds 0.21% in Abbott Laboratories (NYSE:ABT) or 7,400 shares. Therefore 72% are positive. Zuckerman Investment Group LLC's holdings in Abbott Laboratories were worth $4,029,000 at the end of the most recent reporting period. The firm earned "Overweight" rating on Tuesday, January 2 by Morgan Stanley. BTIG Research downgraded Abbott Laboratories (NYSE:ABT) on Monday, January 22 to "Neutral" rating. The stock has "Overweight" rating by Barclays Capital on Thursday, January 25. Papp L Roy & Assocs has 0.11% invested in Abbott Laboratories (NYSE:ABT). BMO Capital Markets upped their price objective on Abbott Laboratories from $65.00 to $70.00 and gave the stock an "outperform" rating in a research report on Thursday, January 25th. The stock of Visteon Corporation (NASDAQ:VC) has "Equal-Weight" rating given on Friday, October 27 by Barclays Capital. Credit Suisse maintained the shares of SHW in report on Wednesday, October 4 with "Outperform" rating.

Do investors think to respond accordingly to new analyst's rating and change a position based on the analyst's rating opinion without any further research? Goldman Sachs has "Neutral" rating and $90 target.

Like this: